PRIMARY SCLEROSING CHOLANGITIS
Clinical trials for PRIMARY SCLEROSING CHOLANGITIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY SCLEROSING CHOLANGITIS trials appear
Sign up with your email to follow new studies for PRIMARY SCLEROSING CHOLANGITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare liver disease: elafibranor trial underway
Disease control OngoingThis study tests a drug called elafibranor in 68 adults with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. The main goal is to check the drug's safety and side effects compared to a placebo. Researchers will also measure changes in blood test…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated May 26, 2026 11:16 UTC
-
Could ditching gluten ease two tough gut diseases?
Disease control OngoingThis study looks at whether a gluten-free diet can help people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD). Researchers will track changes in liver enzymes, gut bacteria, and symptoms in 60 adults over time. The goal is to see if avoiding gluten…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: NA • Sponsor: Institute for Clinical and Experimental Medicine • Aim: Disease control
Last updated May 26, 2026 11:11 UTC
-
Could a common cholesterol drug help PSC patients live longer?
Disease control OngoingThis study tests whether taking simvastatin daily for 5 years can improve survival and reduce serious complications like liver failure, cancer, or bleeding in people with primary sclerosing cholangitis (PSC). About 560 adults with PSC will receive either simvastatin or a placebo.…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE3 • Sponsor: Annika Bergquist • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for rare liver disease: experimental drug CS0159 enters phase 2 trial
Disease control OngoingThis study tests a new drug called CS0159 in 50 adults with primary sclerosing cholangitis (PSC), a rare liver disease. The goal is to see if the drug is safe and can improve liver health by lowering certain liver enzyme levels. Participants will receive either CS0159 or a placeb…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug aims to stop the itch of a rare liver disease
Symptom relief OngoingThis study tests a drug called volixibat to see if it can reduce severe itching caused by primary sclerosing cholangitis (PSC), a rare liver disease. About 182 people aged 12 and older with PSC-related itching will receive either volixibat or a placebo. The main goal is to measur…
Matched conditions: PRIMARY SCLEROSING CHOLANGITIS
Phase: PHASE2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 26, 2026 11:19 UTC